Hormonal
Carbohydrate-restricted nutrition therapy (CRNT) supported by continuous remote care enables the deprescription of GLP-1 receptor agonists in people with type 2 diabetes without regression of glycemic control or body weight loss.
If you are on a GLP-1 drug (like Ozempic or Wegovy) for Type 2 Diabetes or weight, you do not necessarily have to take it forever. This study suggests that if you adopt a medically-supervised ketogenic diet (low carb, high healthy fat) and monitor your blood ketones, you may be able to stop the drug while keeping your weight and blood sugar stable. The key is that the diet reduces hunger hormones, doing the job the drug was doing, allowing you to step off the medication without regaining weight.
These results demonstrate that CRNT in a continuous remote care model provides an effective GLP-1 step-off and maintenance therapy, allowing patients to discontinue GLP-1 while maintaining body weight loss and glycemia below therapeutic targets.
Why this rating
The study is a retrospective, propensity-score matched cohort study (real-world data), not a randomized controlled trial, introducing potential confounding despite matching.
Source
Effect of Glucagon-Like Peptide-1 Deprescription Following Nutrition Therapy via Telemedicine on Glycemia and Body Weight among People with Type 2 Diabetes in a Real-World Setting: A Propensity Score Matched Cohort Study
Amy L. McKenzie et al. · medRxiv · 2023
DOI 10.1101/2023.06.18.23291518
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →